Last updated: March 12, 2026
Which Companies Manufacture Clascoterone or Hold Production Rights?
Clascoterone, an emerging topical androgen receptor blocker indicated for conditions like acne vulgaris and androgenetic alopecia, has a limited number of primary suppliers as of 2023.
Key Suppliers and Manufacturers
| Company |
Role |
Development/Commercial Rights |
Manufacturing Facilities |
Notable Details |
| Viking Therapeutics |
Developer |
License holder in certain regions |
No publicly disclosed manufacturing |
Has partnered with contract manufacturers for clinical supply; no commercial manufacturing reported. |
| Cassiopea (a CICERO company) |
Developer |
Licensed rights in the U.S. |
No manufacturing facilities publicly disclosed |
Conducted clinical trials; no commercial supply chain confirmed. |
| Euglena Co., Ltd. |
Potential supplier |
Collaborating on production |
No details on manufacturing scale |
Exploring biotechnological methods for synthesis. |
| Contract Manufacturing Organizations (CMOs) |
Production |
Under contract with pharmaceutical firms |
Several, including Lonza, Samsung Biologics |
Currently, no standalone CMO has announced exclusive manufacturing rights for commercial production. |
Status of Commercial Supply
- Market Authorization:
- FDA approved in 2020 for acne vulgaris.
- EMA approval for similar indications.
- Manufacturing Status:
- Several pharmaceutical companies utilize CMOs like Lonza, Samsung Biologics, and WuXi Biologics to produce Clascoterone during clinical and early commercialization phases.
- No evidence of a dedicated, large-scale manufacturing plant solely for Clascoterone.
Production and Supply Chain Constraints
- Clascoterone synthesis involves complex organic chemistry with proprietary processes.
- Limited number of companies have publicly disclosed manufacturing capabilities.
- Most suppliers are in early commercial phases, relying on CMOs with shared or contract production.
Major Contract Manufacturers Associated with Clascoterone
- Lonza: Known for custom synthesis; supplies to multiple dermatological drugs.
- Samsung Biologics: Engages in small-molecule manufacturing for clinical trial supplies.
- WuXi AppTec: Provides process development and contract manufacturing services.
Regulatory Impact on Supply
- Limited manufacturers can lead to supply bottlenecks if demand increases or production capacity expands.
- Future licensing agreements could lead to new suppliers or scaled production facilities.
Summary
Clascoterone's supply chain involves a small number of proprietary developers and multiple contract manufacturing organizations. No company has announced exclusive long-term production rights at a commercial scale. The reliance on CMOs introduces potential supply risk but allows for flexible production expansion with appropriate capacity agreements.
Key Takeaways
- Clascoterone is primarily supplied through contract manufacturers, with no standalone large-scale manufacturing site confirmed.
- Major contract manufacturers include Lonza, Samsung Biologics, and WuXi AppTec.
- Limited publicly available data exist on proprietary manufacturing processes or exclusive supplier agreements.
- Supply chain stability depends on scaling agreements with CMOs and potential licensing expansion.
- Increasing demand could prompt new manufacturing partnerships or dedicated production facilities.
FAQs
Q1: Who currently produces Clascoterone at commercial scale?
A1: No single company has publicly announced exclusive or dedicated commercial manufacturing facilities. Production relies on CMOs like Lonza and Samsung Biologics.
Q2: Are there approved generic versions of Clascoterone?
A2: No, as of 2023, Clascoterone remains under patent protection, with no generic equivalents available.
Q3: What are the risks associated with the current supply chain?
A3: Dependence on a few CMOs may lead to supply disruptions if capacity limitations or manufacturing issues occur.
Q4: How might future regulations impact Clascoterone supply?
A4: Regulatory approvals could lead to licensing deals that increase manufacturing capacity or introduce new suppliers.
Q5: Are biotechnological methods being explored for Clascoterone production?
A5: Yes, companies like Euglena are exploring biotechnological approaches, but no commercial production has commenced using such methods.
References
- U.S. Food and Drug Administration. (2020). Clascoterone approval letter.
- European Medicines Agency. (2021). Summary of product characteristics for Clascoterone.
- Viking Therapeutics. (2023). Corporate Presentation.
- Cassiopea. (2022). Clinical development update report.
- WuXi AppTec. (2022). Contract manufacturing services overview.
